Management of patients with an impaired ovarian reserve or poor ovarian response (POR) to exogenous gonadotropin stimulation has challenged reproductive specialists for years. Apart from the limited understanding of its pathophysiology, there is wide heterogeneity in defining POR and overall disappointing outcomes in assisted reproductive technology (ART) cycles.
The First POSEIDON’s World Conference will dissect the new POSEIDON criteria as a means to improve the management of patients exposed to assisted reproductive technology. The new criteria enable discussion of novel approaches catered specifically to patients with low prognosis during IVF, thereby offering better tools to optimise IVF success rates.
The programme will engage renowned international experts with vast clinical experience in constantly evolving subjects. The programme aims to impart specific knowledge with focus on changing concepts or practices.
With this conference, the participants will get acquainted with the state-of-the-art definition of impaired response to ovarian stimulation, comprehend the new low prognosis concept and its application in clinical practice, and individualise and manage women with expected or unexpected prognosis to ART as per the POSEIDON classification.
The program is intended for clinicians, embryologists, andrologists, scientists, and managers working in ART who wish to update their knowledge of advanced techniques and scientific innovations and understand best practices using evidence-based models of care.
This programme will be submitted for CME accreditation to EACCME® (European Accreditation Council for Continuing for Medical Education).
Through an agreement between the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), physicians may convert EACCME credits to an equivalentnumber of AMA PRA Category 1 Credits TM . Information on the process to convert EACCME credit to AMA credit can be found at https://edhub.ama-assn.org/pages/applications.
This programme is designed in partnership with the Portuguese Society of Reproductive Medicine.
The idea of the founding of the Portuguese Society of Reproductive Medicine arose in 1975 during an informal conversation between Portuguese specialists participating in the IFFS (Federation of Fertility and Sterility Societies) meeting in Buenos Aires. It formally materialised with the publication of its statutes in Diário da República in 1978.
According to this legal text, the SPMR has as its objective the scientific and technological development in the field of reproductive medicine, seeking to incentivise basic and applied research.
Federico II University
Centre for Reproductive Medicine & Gynaecological Endocrinology
Federico II University
Sandro C. Esteves
Androfert – Andrology and Human Reproduction Clinic
Fertility Centre Hamburg
Skive Regional Hospital and Faculty of Health
Antonio La Marca
University of Modena and Reggio Emilia
Clinical Activity of Clinica Eugin Modena
Thi Ngoc Lan Vuong
University of Medicine and Pharmacy at Ho Chi Minh City
Ho Chi Minh City, Vietnam
Filippo Maria Ubaldi
G.E.N.E.R.A. Centre for Reproductive Medicine
Sesh K. Sunkara
King’s College London
Hospital Center São João
9 - 10 September 2022
L1 – Why we need new criteria for the low prognosis patient: a historical overview
Carlo Alviggi, Italy
L2 – The POSEIDON criteria explained
Peter Humaidan, Denmark
L3 – Female age, oocyte competence and beyond: the relevance for the POSEIDON criteria
Filippo Ubaldi, Italy
L4 – Antral follicle count and anti-Mullerian hormone: essential pillars of the POSEIDON criteria
Antonio La Marca, Italy
L5 – The oocyte number and the relationship with low prognosis
Sesh K. Sunkara, UK
L6 – FSH and LH deficiency in MAR treatments: advanced female age, treatment factors and genetics
Pedro Xavier, Portugal
L7 – Ovarian hypo-response to COS and its proposed metrics: The FORT and the FOI
Alessandro Conforti, Italy
L8 – The ART calculator: a validated tool to predict reproductive success in ART
Sandro Esteves, Brazil
L9 – The POSORT guidelines: improving study design and reporting of clinical trials
Raoul Orvieto, Israel
L10 – POSEIDON in clinical practice: incidence and characteristics: insights from multinational real-world data
Hakan Yarali, Turkey
L11 – Cumulative Live Birth Rates in POSEIDON patients: real-world evidence
Lan Vuong, Vietnam
L12 – Management strategies in POSEIDON groups 1 and 2 patients
Klaus Bühler, Germany
L13 – Management strategies in POSEIDON groups 3 and 4 patients
Robert Fischer, Germany
L14 – The POSEIDON group: what did we achieve and what’s next? (Optional)
Carlo Alviggi, Italy
The official language of the activity will be English. Simultaneous translation (from/to English/Chinese/ French/Spanish) will be provided.
For registration information please contact:
EVENT PLANET SRL
Phone: +39 (0)81 552 9399
The registration includes:
• Scientific sessions
• Coffee breaks and lunch
• Educational materials
• Certificate of attendance
Dinner is not included
Due to Covid-19 Situation, the format and date of the conference are subject to change.
Med.E.A Srl educational programmes are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activities are permitted. There may be presentations discussing investigational uses of various products.
These views are the responsibility of the named speakers, and do not represent an endorsement or recommendation on the part of Med.E.A. Srl. Our educational activities are supported by independent grants from the Healthcare business of Merck KGaA, Darmstadt, Germany; Fujifilm Europe B.V., Androfert Andrology & Human Reproduction Clinic; MVZ Fertility Center Hamburg GmbH; University of North Carolina at Chapel Hill; Reproductive Medicine Agency (Nova Clinic).